Author: Qin, Jian; Jones, Robert C.; Ramakrishnan, Ramesh
Title: Studying copy number variations using a nanofluidic platform Document date: 2008_8_18
ID: prsvv6l9_27
Snippet: ERBB2 amplification is well correlated with an aggressive phenotype characterized by reduced response to chemotherapy, high recurrence rate and short survival time and serves as a significant prognostic predictor for breast cancer patients (37, 41) . Trastuzumab (Herceptin), an FDA-approved monoclonal antibody against the ERBB2 protein, has been shown to dramatically increase response rate and extend survival in breast cancer patients with ERBB2 .....
Document: ERBB2 amplification is well correlated with an aggressive phenotype characterized by reduced response to chemotherapy, high recurrence rate and short survival time and serves as a significant prognostic predictor for breast cancer patients (37, 41) . Trastuzumab (Herceptin), an FDA-approved monoclonal antibody against the ERBB2 protein, has been shown to dramatically increase response rate and extend survival in breast cancer patients with ERBB2 amplification. Given Trastuzumab's proven efficacy and substantial benefit in multiple clinical trials, detection of ERBB2 amplification has become critical (42) (43) (44) (45) .
Search related documents:
Co phrase search for related documents- breast cancer patient and clinical trial: 1, 2, 3, 4
- breast cancer patient and monoclonal antibody: 1
- breast cancer patient and response rate: 1, 2
- cancer patient and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- cancer patient and high recurrence: 1, 2
- cancer patient and monoclonal antibody: 1
- cancer patient and prognostic predictor: 1
- cancer patient and proven efficacy: 1
- cancer patient and reduced response: 1, 2
- cancer patient and response rate: 1, 2, 3
- cancer patient and short survival: 1, 2, 3, 4
- cancer patient and short survival time: 1
- cancer patient and substantial benefit: 1
- clinical trial and FDA approve: 1
- clinical trial and high recurrence: 1, 2, 3
- clinical trial and high recurrence rate: 1
- clinical trial and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- clinical trial and multiple clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- clinical trial and prognostic predictor: 1, 2
Co phrase search for related documents, hyperlinks ordered by date